Damora Therapeutics, Inc. is trading 5.3% up now at $21.68, extending a volatile but generally positive run over the past week.
- Wall Street sentiment has turned increasingly bullish, with several firms initiating coverage at Buy or Outperform ratings and setting price targets ranging from the mid-$30s to mid-$40s.
- Positive momentum is further supported by the prior disclosure of a sizable institutional position in the stock, which continues to bolster investor confidence despite mixed broader market conditions.